LY303366 Activity Against Systemic Aspergillosis and Histoplasmosis In Murine Models.

D.ZECKNER, T.BUTLER, C.BOYLAN, B.BOYLL, Y.LIN, P.RAAB, J.SCHMIDTKE AND W.CURRENT.

Abstract: 

LY303366, a semisynthetic analog of echinocandin B, has potent in vitro and in vivo activity against Aspergillus spp., Candida spp., and Histoplasma capsulatum. In murine models of organ recovery. LY303366 was similar to amphotericin B in its activity against Aspergillus fumigatus, both sterilized kidneys at 10 mg/kg IP. Lower parenteral doses of LY303366 (1.0 and 5.0 mg/kg x 4 IP) significantly reduced numbers of A. fumigatus recovered from kidneys (0.7-2.1 logs compared to untreated controls). Orally administered LY303366 sterilized kidneys at 100 mg/kg x 8. Lower oral doses of LY303366 (10 and 25 mg/kg x 8 PO) reduced renal recoveries of A. fumigatus 0.3-0.7 logs. LY303366 was effective in prolonging the survial of immunocompromised mice challenged systemically with A. fumigatus (ED50 19.6 mg/kg x 14 IP). Amphotericin B was more active in this model (ED50 0.6 mg/kg x 5 IP). Orally administered LY303366 significantly extended survival times compared to untreated aspergillosis controls (ED50 >50 mg/kg x 14 PO). LY303366 was also effective in prolonging the survival of immunosuppressed mice challenged IV with H. capsulatum (ED50
1993

abstract No: 

NULL

Full conference title: 

ICAAC 33rd, 1993
    • ICAAC 33rd